

MOST URGENT



**NO. SO(RMC)2-21/2025
GOVERNMENT OF THE PUNJAB
SPECIALIZED HEALTHCARE &
MEDICAL EDUCATION DEPARTMENT
(TECHNICAL WING)**

Dated Lahore, the 3rd October, 2025

To

- ✓
1. Vice Chancellors of all public sector Medical Universities in Punjab
 2. Principals / Deans / EDs of all public sector Medical Colleges / Specialized Medical Institutions in Punjab
 3. Medical Superintendents of all public sector Teaching Hospitals in Punjab

Subject: **REGULATORY ACTION AGAINST FALSIFIED DRUG PRODUCTS
MANUFACTURED BY UNLICENSED / UNAUTHORIZED ENTITIES**

I am directed to refer the subject cited above and to enclose herewith copy of a letters No. F.13-30/2024-DD(QA-V-III)-P-001 dated 10.09.2025, received from the Deputy Director-IX (QA & LT), Drug Regulatory Authority of Pakistan, Division of Quality Assurance & Laboratory Testing, Prime Minister's National Health Complex, Islamabad.

2. Submitted for information and further necessary action.


SECTION OFFICER (RMC)

NO & DATE EVEN:

Copy is forwarded for information to the:

1. Deputy Director-IX (QA & LT), Drug Regulatory Authority of Pakistan, Division of Quality Assurance & Laboratory Testing, Prime Minister's National Health Complex, Islamabad w/r to letter referred above.
2. PSO to Secretary to Government of the Punjab, Specialized Healthcare & Medical Education Department.
3. PS to Special Secretary (Operations), Specialized Healthcare & Medical Education Department.
4. P.A. to Additional Secretary (Technical), Specialized Healthcare & Medical Education Department.


SECTION OFFICER (RMC)



F. 13-30/2024-DD(QA-VIII)-P-001
Government of Pakistan
Drug Regulatory Authority of Pakistan
Quality Assurance & Laboratory Testing Division

MOST IMMEDIATE

Islamabad, the 10th September, 2025.

Subject: **REGULATORY ACTION AGAINST FALSIFIED DRUG PRODUCTS MANUFACTURED BY UNLICENSED / UNAUTHORIZED ENTITIES.**

I am directed to inform that several drug product samples submitted to the **Directorate of Drugs Control Punjab** have been confirmed as **falsified/spurious** upon testing by Drug Testing Laboratories of Punjab. The laboratory reports have indicated that These products were found to be manufactured/distributed by unauthorized entities and, in some cases, contain no active pharmaceutical ingredient (API). Details of the affected products and batches are enclosed for reference.

S#	Product Name	Batch No.	Purported Manufacturer	Remarks
1	TABLET ONSET-8 (REG # 025989) Each Tablet Contains: ondansetron HCl eq. To ondansetron 8 mg)	447	Purported to be manufactured by M/s Pharmedic Laboratories (Pvt) Ltd. (DML # 000228) 16 Km Multan Road Lahore.	Drug Testing Laboratory, Rawalpindi Punjab declared the purported drug product as ' Spurious ' as defined under clause (i) of subsection (z-b) of Section 3 of the Drugs Act, 1976.
2	Capsule Nexum (Reg # 033891) EACH Capsule contains: ENTERIC-COATED PELLETS OF ESOMEPRAZOLE MAGNESIUM TRIHYDRATE EQUIVALENT TO ESOMPERAZOLE 40 MG)	C02085	Purported to be manufactured by M/s GETZ PHARMA (PVT) LIMITED., PLOT NO. 01, SECTOR 25, KORANGI INDUSTRIAL AREA. KARACHI.	Drug Testing Laboratory, Rawalpindi Punjab declared the purported drug product as ' Spurious ' as defined under clause (i) of subsection (z-b) of Section 3 of the Drugs Act, 1976.
3	Capsule Maxflow -D (Reg # 033891) EACH Capsule contains: Extended release pellets of Tamsulosin HCl eq. to Tamsulosin HCl 0.4mg	QM375	Purported to be manufactured by M/s CCL Pharmaceuticals (Pvt.) Ltd. (DML # 000052) 62 Industrial Estate Kot Lakhpat Lahore.	Drug Testing Laboratory, Multan Punjab declared the purported drug product as ' Spurious with regard to Dutasteride, misbranded with regard to labelling & substandard on basis of dissolution test and assay of tamsulosin HCl'.
	Capsule Azomax 250 mg Each Capsule contains:	C3193	Purported to be manufactured by M/s AGP Ltd. (DML # 000348)	Drug Testing Laboratory, Rawalpindi Punjab declared the purported drug product

DIARY NO. 723
DATE 17-9-2025
SO (P-I) SHC&ME DEPT.

1 (Proc) SHC&ME Deptt.
Diary No. 5774
Date: 17/9/25

PA to A.S	
(PROCUREMENT)	
PUC No.	15/09/25
SO (P-I)	SO (Stand)
SO (P-II)	BME
SO (P-III)	C. Manager
SO (P-IV)	DS (Proc)

Secretal Secretary (D&R)	
Diary No.	
Date: 15-9	
AS (D)	AS (F)
AS (P)	AS (ME)
CPO	SM&IPU
AS	DS

SECRETARY SHC&ME	
Diary No. 8233	
Date: 15/9/25	
SS (OPS)	SS (D&R)
ASA	SD
ASE	
AST	
DS ()	0
SLD	1000


SLON

05

	Azithromycin (as di-hydrate) 250 mg		Plot No. B-23 Sindh Industrial Trading Estate Karachi.	as ' Spurious ' as defined under clause (i) of subsection (z-b) of Section 3 of the Drugs Act, 1976. (DDCP Alert No. 171/2025)
5	PAYODEN Solution 60mL Each 100ml contains: Povidone-Iodine.10.0g eq. to 1.0g available Iodine (1%w/v)	006	Purported to be manufactured by an unlicensed /illegal entity claimed to be M/s MSL Laboratories Industrial Area, Karachi.	Drug Testing Laboratory, Punjab declared the purported drug product as ' Spurious ' as defined under clause (i) of subsection (z-b) of Section 3 of the Drugs Act, 1976. (DDCP Alert No. 171/2025)
6	Tablet Rigix Each film coated tablet contains: Cetirizine hydrochloride.....10mg	C3905 C3362	Purported to be manufactured by M/s AGP Ltd. (DML # 000348) Plot No. B-23 Sindh Industrial Trading Estate Karachi. (Recovered from unauthorized person / paddler)	Drug Testing Laboratory, Punjab declared the purported drug product as ' Spurious ' as defined under clause (i) of subsection (z-b) of Section 3 of the Drugs Act, 1976. Note: The unit carton bears batch # C3905 while blister bears Batch # C3362. (DDCP Alert No. 171/2025)
7	Fexet Tablet 120mg Each film coated tablet contains: Fexofenadine hydrochloride.120mg	F26018	Purported to be manufactured by M/s Getz Pharma (Pvt) Limited., Plot No. 01, Sector 25, Korangi Industrial Area, Karachi.	Drug Testing Laboratory, Punjab declared the purported drug product as ' Spurious ' as defined under clause (i) of subsection (z-b) of Section 3 of the Drugs Act, 1976. (DDCP Alert No. 171/2025)
8	Capsule Zetro 250 mg Each Capsule contains: Azithromycin (as dihydrate)250 mg	247C21	Purported to be manufactured by M/s Getz Pharma (Pvt) Limited., 29-30 Sector 27 Korangi Industrial Area Karachi. (Recovered from unauthorized person / paddler)	Drug Testing Laboratory, Punjab declared the purported drug product as ' Spurious ' as defined under clause (i) of subsection (z-b) of Section 3 of the Drugs Act, 1976. (DDCP Alert No. 171/2025)
9	Tablet Duphaston Each film coated tablet contains: Dydrogesterone ... 10mg	241476	Purported to be manufactured by M/s Highnoon Laboratories Ltd. 17.5 Km Multan Road Lahore. (DML # 000155) (Recovered from unauthorized person / paddler)	Drug Testing Laboratory, Punjab declared the purported drug product as ' Spurious ' as defined under clause (i) of subsection (z-b) of Section 3 of the Drugs Act, 1976.

06

				(DDCP Alert No. 176/2025)
10	Tablet Danzen DS Each enteric coated tablet contains: Serratiopeptidase 10 mg (20,000 units of Serratiopeptidase)	3602	Purported to be manufactured by M/s Helix Pharma (Pvt) Ltd. A/56 SITE Mangopir Karachi. (DML # 000030) <i>(Recovered from unauthorized person / paddler)</i>	Drug Testing Laboratory, Punjab declared the purported drug product as 'Spurious' as defined under clause (i) of subsection (z-b) of Section 3 of the Drugs Act, 1976. (DDCP Alert No. 176/2025)
11	Tablet Terbisil Each Tablet contains: Terbinafine (as HCl) 250 mg	473	Purported to be manufactured by M/s Saffron Pharmaceuticals (Pvt) Ltd. (DML # 000616) 19-Km Shekhupura Road Faisalabad. <i>(Recovered from unauthorized person / paddler)</i>	Drug Testing Laboratory, Punjab declared the purported drug product as 'Spurious' as defined under clause (i) of subsection (z-b) of Section 3 of the Drugs Act, 1976. (DDCP Alert No. 176/2025)
12	Tablet Terbisil Each Tablet contains: Terbinafine (as HCl) 250 mg	473	Purported to be manufactured by M/s Helix Pharma (Pvt) Ltd. A/56 SITE Mangopir Karachi. (DML # 000030) <i>(Recovered from unauthorized person / paddler)</i>	Drug Testing Laboratory, Punjab declared the purported drug product as 'Spurious' as defined under clause (i) of subsection (z-b) of Section 3 of the Drugs Act, 1976. (DDCP Alert No. 176/2025)
13	Tablet Azomax 500 mg Each film coated tablet contains : Azithromycin (as di-hydrate)500 mg	C3670	Purported to be manufactured by M/s AGP Ltd. (DML # 000348) Plot No. B-23 Sindh Industrial Trading Estate Karachi. <i>(Recovered from unauthorized person / paddler)</i>	Drug Testing Laboratory, Punjab declared the purported drug product as 'Spurious' as defined under clause (i) of subsection (z-b) of Section 3 of the Drugs Act, 1976. (DDCP Alert No. 178/2025)
14	Tablet Prism 10 mg Each tablet contains: Escitalopram oxalate eq. to escitalopram 10 mg	25PR02	Purported to be manufactured by M/s Friends Pharma (Pvt) Ltd. (DML # 000531) 31-Km Ferozepur Road Lahore. <i>(Recovered from unauthorized person / paddler)</i>	Drug Testing Laboratory, Punjab declared the purported drug product as 'Spurious' as defined under clause (i) of subsection (z-b) of Section 3 of the Drugs Act, 1976. (DDCP Alert No. 178/2025)



07

15	Capsule Gabica 300mg Pregabalin 100mg	427C27	Purported to be manufactured by M/s Getz Pharma (Pvt) Limited., 29-30 Sector 27 Korangi Industrial Area Karachi. <i>(Recovered from unauthorized person / paddler)</i>	Drug Testing Laboratory, Punjab declared the purported drug product as 'Spurious' as defined under clause (i) of subsection (z-b) of Section 3 of the Drugs Act, 1976. <i>(DDCP Alert No. 178/2025)</i>
16	Tablet Ativan 2 mg Each tablet contains: Lorazepam 2 mg	17C7019	Purported to be manufactured by M/s Pfizer Pakistan Ltd. B-2, S.I.T.E. Karachi. <i>(Recovered from unauthorized person / paddler)</i>	Drug Testing Laboratory, Punjab declared the purported drug product as 'Spurious' as defined under clause (i) of subsection (z-b) of Section 3 of the Drugs Act, 1976. <i>(DDCP Alert No. 178/2025)</i>
17	Injection ONSET 4 ml ondansetron HCl eq. To ondansetron 2mg/ml)	829	Purported to be manufactured by M/s Pharmedic Laboratories (Pvt) Ltd. (DML # 000228) 16 Km Multan Road Lahore. <i>(Recovered from unauthorized person / paddler)</i>	Drug Testing Laboratory, Rawalpindi Punjab declared the purported drug product as 'Spurious' and 'substandard' on the basis of assay. <i>(DDCP Alert No. 178/2025)</i>

02. In view of the serious **public health risk** posed by these Spurious / unauthorized products, the following actions are advised for immediate implementation:

- i. **Conduct market surveillance** in your respective jurisdiction to identify and report the presence of these falsified products.
- ii. **Seize available stock** from distributors, retailers, or unauthorized sellers under the provisions of the **Drugs Act, 1976** and applicable provincial laws.
- iii. **Coordinate with local law enforcement** where necessary for action against illegal manufacturing and distribution activities.
- iv. **Lodge formal complaints/FIRs** against parties involved in the manufacture, sale, or distribution of such spurious medicines.

03. This communication has been issued under the mandate of **Section 18 of the Drugs Act, 1976**, read with the **DRAP Act, 2012**, and aims to safeguard public health from illegal and harmful therapeutic goods. The matter may please be treated as most urgent and submit a **compliance and action report** to DRAP Headquarters (QA< Division) within **7 working days**.

02

(SALATEEN WASEEM PHILIP)
Deputy Director-IX (QA<)

Distribution:

Copy for information and necessary action – with request to issue necessary directions to points of use/sale under administrative control/ fall under area of jurisdiction to ensure recall of defective product from the market, please.

1. The Secretary (SHC&ME) Health Department (Government of Punjab).
2. The Secretary Health & Population Department (Government of Punjab).
3. The Secretary Health Department (Government of Sindh).
4. The Secretary Health Department (Government of KP).
5. The Secretary Health Department (Government of Baluchistan).
6. The Secretary, Ministry of Health (Government of AJ&K).
7. The Additional Director, DRAP, Islamabad, Lahore, Karachi, Peshawar & Quetta.
8. Chief Drugs Controller/Inspector Punjab, Sindh, Khyber Pukhtunkhwa, Balochistan, Gilgit-Baltistan, Azad Jammu & Kashmir and Senior Drug Inspector ICT Islamabad.
9. Pakistan Pharmacists Association (PPA) to advise your members to remain vigilant and to counsel patients regarding the dangers of falsified medicines.
10. Pakistan Pharmaceutical Manufacturers Association (PPMA)
11. Office Copy


10/09/2025
Deputy Director-IX (QA<)